Mabion will use the financing for a wide-ranging Research and Development programmes.
The European Investment Bank (EIB) on 24th of October agreed to lend EUR 30 million to Mabion, a Polish biotech company, to finance its growth plans.
How does EIB loan help young biotech sector?
According to EIB’s statement, Mabion will use the financing for a wide-ranging research and development programme, conducting clinical trials, as well as expending its manufacturing capacities with state-of-the-art equipment.
The company expects to employ 96 additional staff as a result of this financial booster.
The project is the first in Poland to benefit from the EFSI-backed European Growth Finance Facility, which specialises in venture debt.
